Enhancing Clinicians’ Knowledge And Competence Regarding The Diagnosis And Treatment Of Hypertrophic Cardiomyopathy: Effectiveness Of Continuing Medical Education

Meghan Coulehan,Tamima Ashraf,Emily Kitterman,Samantha Hynes,Anjali Owens,Milind Desai
DOI: https://doi.org/10.1016/j.cardfail.2023.10.236
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:The diagnosis and management of hypertrophic cardiomyopathy (HCM) is challenging. HCM is often missed in patients, leading to potentially devastating consequences. Until recently, treatment options could only address disease symptomatology. However, the therapeutic landscape has recently evolved with the approval of a novel drug class, cardiac myosin inhibitors, that can target the underlying disease pathophysiology. Given the emergence of this novel treatment approach, there is a renewed need to improve clinicians’ understanding of how to optimally diagnose HCM and how to translate the latest data on novel therapies into practice. We developed a continued medical education (CME) program aimed at improving clinicians’ knowledge and competence related to understanding guideline-recommended methods for diagnosing HCM, describing clinical impact of cardiac myosin inhibitors, and identifying strategies for evidence-based care. On Nov 5, 2022, a 60-minute CME-certified, interactive symposium titled “Integrating Novel Cardiac Myosin Inhibitors into the Management of Hypertrophic Cardiomyopathy: Practical Strategies for Diagnosis and Treatment”, presented by two cardiologists with expertise in HCM, took place at the American Heart Association's Scientific Sessions. Learners could participate in three different ways- 1) in person, 2) by attending virtually, or 3) by watching the full audiovisual replay following the live event. Changes in knowledge and competence were measured using pre- and post-test learner analysis. Assessments were scored in aggregate and at the individual level to compare between specialty audiences. Practice change and patient impact were also measured. As of Nov 28, 2022, a total of 388 learners participated, with the leading learner specialties being internal medicine specialists (52%) and cardiologists (36%). Across specialties, baseline knowledge was lowest regarding risk assessment of patients with HCM and patient eligibility criteria for novel cardiac myosin inhibitors. A subset of learners (n=108) completed pre- and post-test assessments. Of these learners, post-education, 34% improved knowledge related to guideline-recommended diagnosis of HCM, 21% improved knowledge on the clinical profiles of cardiac myosin inhibitors and 33% showed improved competence on incorporating these novel therapies into practice. Of the learners, 81% expressed their intention to make changes to their practice based on the activity. Based on learners’ self-report of number of patients seen per week, this program potentially impacted care of 822 patients. More than 50% of the learners also expressed interest in learning about adverse event management associated with cardiac myosin inhibitors and receiving further education via case examples related to HCM management. Our findings showed that hybrid CME was effective in improving knowledge and competence among clinicians related to the diagnosis and treatment of HCM. Our results also imply that there is an ongoing need and interest among clinicians to learn more about these topics.
cardiac & cardiovascular systems
What problem does this paper attempt to address?